1. Home
  2. TRIN vs ABCL Comparison

TRIN vs ABCL Comparison

Compare TRIN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$16.84

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.47

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
ABCL
Founded
2007
2012
Country
United States
Canada
Employees
109
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TRIN
ABCL
Price
$16.84
$5.47
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$16.00
$8.40
AVG Volume (30 Days)
941.6K
6.5M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
12.61%
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
$30.41
N/A
Revenue Next Year
$10.00
$21.85
P/E Ratio
$7.18
N/A
Revenue Growth
N/A
160.56
52 Week Low
$13.76
$2.75
52 Week High
$17.38
$6.79

Technical Indicators

Market Signals
Indicator
TRIN
ABCL
Relative Strength Index (RSI) 50.40 53.87
Support Level $16.56 $5.34
Resistance Level $17.31 $5.63
Average True Range (ATR) 0.29 0.52
MACD -0.05 -0.08
Stochastic Oscillator 18.80 24.44

Price Performance

Historical Comparison
TRIN
ABCL

About TRIN Trinity Capital Inc.

Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: